ReviewDrugs2003
Current management strategies for coexisting diabetes mellitus and obesity.
Review in Drugs, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 94 citations in OpenAlex.
- Mapping Obesity Trends in Saudi Arabia: A Four-Year Description Study.Healthcare (Basel, Switzerland) · 2024Article
- Novel oxadiazole derivatives as potent inhibitors of α-amylase and α-glucosidase enzymes: Synthesis,Iranian journal of basic medical sciences · 2021Article
- Sex differences in oxidative stress level and antioxidative enzymes expression and activity in obese pre-diabetic elderly rats treated with metformin or liraglutide.Croatian medical journal · 2021Article
- ZnO nanoparticles and their acarbose-capped nanohybrids as inhibitors for human salivary amylase.IET nanobiotechnology · 2017Article
- Associations of A-FABP with Anthropometric and Metabolic Indices and Inflammatory Cytokines in Obese Patients with Newly Diagnosed Type 2 Diabetes.BioMed research international · 2016Article
- Obesity pharmacotherapy: current status.EXCLI journal · 2015Article
- Cardiovascular effects of gliptins.Nature reviews. Cardiology · 2013Review
- Childhood obesity: a life-long health risk.Acta pharmacologica Sinica · 2012Review
- Sibutramine on cardiovascular outcome.Diabetes care · 2011Review
- Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.Clinical pharmacokinetics · 2010Review
- Site-specific modulation of white adipose tissue lipid metabolism by oleoyl-estrone and/or rosiglitazone in overweight rats.Naunyn-Schmiedeberg's archives of pharmacology · 2010Article
- Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.Clinical pharmacokinetics · 2007Review
- Pharmacokinetic interactions with thiazolidinediones.Clinical pharmacokinetics · 2007Review
- The metabolic syndrome - background and treatment.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2006Review
- Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update.Drug safety · 2005Review
- Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies.The Clinical biochemist. Reviews · 2004Article
- Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.Drugs · 2004Review
- Review
- Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?Drugs · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Besides genetic predisposition, obesity is the most important risk factor for the development of diabetes mellitus. Weight reduction has been shown to markedly improve blood glucose control and vascular risk factors associated with insulin resistance in obese individuals with type 2 diabetes. Therapeutic strategies for the obese diabetic patient include: (i) promoting weight loss, through lifestyle modifications (low-calorie diet and exercise) and antiobesity drugs (orlistat, sibutramine, etc.); (ii) improving blood glucose control, through agents decreasing insulin resistance (metformin or thiazolidinediones, e.g. pioglitazone and rosiglitazone) or insulin needs (alpha-glucosidase inhibitors, e.g. acarbose) in preference to agents stimulating defective insulin secretion (sulphonylureas, meglitinide analogues); and (iii) treating common associated risk factors, such as arterial hypertension and dyslipidaemias, to improve cardiovascular prognosis. Whenever insulin is required by the obese diabetic patient after failure to respond to oral drugs, it should be preferably prescribed in combination with an oral agent, more particularly metformin or acarbose, or possibly a thiazolidinedione. When morbid obesity is present, both restoring a good glycaemic control and correcting associated risk factors can only be obtained through a marked and sustained weight loss. This objective justifies more aggressive weight reduction programmes, including very-low-calorie diets and bariatric surgery, but only within a multidisciplinary approach and long-term strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.